Amneal Acquires Kashiv for $750M, Raises Outlook

Amneal Pharmaceuticals announced its acquisition of Kashiv for $750 million, which has led to a raised FY26 EPS outlook. The company also anticipates deleveraging below 3x by 2028 and targets $4.3B-$4.5B in revenue by 2030.